

Vandervelpen Nico  
Form 4  
July 26, 2017

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Vandervelpen Nico

2. Issuer Name and Ticker or Trading Symbol  
Minerva Neurosciences, Inc.  
[NERV]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction  
(Month/Day/Year)  
07/24/2017

Director  10% Owner  
 Officer (give title below)  Other (specify below)

C/O MINERVA  
NEUROSCIENCES, INC., 1601  
TRAPELO ROAD, SUITE 284

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

WALTHAM, MA 02451

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|
|                                 |                                      |  |                                | (A) or (D)  | Price   |  |                                   |
|                                 |                                      |  |                                | Code  | V   | Amount   |                                   |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

Edgar Filing: Vandervelpen Nico - Form 4

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code |   |     | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) |                  | 6. Date Exercisable and Expiration Date (Month/Day/Year) |              | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) |  |
|--|--|--------------------------------------|--|---------------------|---|-----|---|------------------|--|--------------|---|--|
|  |  |                                      |  | Code                | V | (A) | (D)   | Date Exercisable | Expiration Date  | Title        | Amount or Number of Shares                                    |  |
| Stock Option (Right to Buy)                | \$ 4.71  | 07/24/2017                           |  | D <sup>(1)</sup>    |   |     | 25,000  | <u>(1)</u>       | 12/03/2025   | Common Stock | 25,000  |  |
| Stock Option (Right to Buy)                | \$ 4.71  | 07/24/2017                           |  | A <sup>(1)</sup>    |   |     | 25,000  | <u>(1)</u>       | 07/24/2018   | Common Stock | 25,000  |  |
| Stock Option (Right to Buy)                | \$ 10.2  | 07/24/2017                           |  | D <sup>(2)</sup>    |   |     | 12,500  | <u>(2)</u>       | 06/15/2026   | Common Stock | 12,500  |  |
| Stock Option (Right to Buy)                | \$ 10.2  | 07/24/2017                           |  | A <sup>(2)</sup>    |   |     | 12,500  | <u>(2)</u>       | 07/24/2018   | Common Stock | 12,500  |  |
| Stock Option (Right to Buy)                | \$ 10  | 07/24/2017                           |  | D <sup>(3)</sup>    |   |     | 12,500  | <u>(3)</u>       | 05/31/2027   | Common Stock | 12,500  |  |
| Stock Option (Right to Buy)                | \$ 10  | 07/24/2017                           |  | A <sup>(3)</sup>    |   |     | 12,500  | <u>(3)</u>       | 07/24/2018   | Common Stock | 12,500  |  |

## Reporting Owners

| Reporting Owner Name / Address  | Relationships |           |         |       |
|---|---------------|-----------|---------|-------|
|   | Director      | 10% Owner | Officer | Other |
| Vandervelpen Nico<br>C/O MINERVA NEUROSCIENCES, INC.<br>1601 TRAPELO ROAD, SUITE 284<br>WALTHAM, MA 02451 | X             |           |         |       |

## Signatures

/s/ Nico

Vandervelpen

07/26/2017

\_\_Signature of  
Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on December 4, 2015 and provides for vesting quarterly over 3 years beginning on December 4, 2015.

(2) The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 16, 2016 and provides for vesting in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following June 16, 2016 and an additional 1/4 every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date.

(3) The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 1, 2017 and provides for vesting in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following June 1, 2017 and an additional 1/4 every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.